Recent Advances in Molecular Biomarkers in Multiple Myeloma

August 10th 2022

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

Tools to Guide Treatment Decisions in Breast Cancer

August 5th 2022

Mark Pegram, MD, and Lee Schwartzberg, MD, FACP, have a discussion on the management of early-stage hormone-receptor-positive breast cancer and the tools available to help inform treatment decisions.

My Treatment Approach: Metastatic Triple-Negative Breast Cancer

July 18th 2022

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Updates in Treatment and Management of Chemotherapy-induced Myelosuppression

July 8th 2022

Two experts in the management of extensive-stage small cell lung cancer provide an overview of chemotherapy-induced myelosuppression and share key insights into the myeloprotective benefit of the CDK4/6 inhibitor trilaciclib.

Tamibarotene in Newly Diagnosed Acute Myeloid Leukemia (AML)

June 17th 2022

Dr Daniel Pollyea comments on the potential use of tamibarotene in patients that are newly diagnosed with acute myeloid leukemia (AML).

Tamibarotene in Higher-Risk Myelodysplastic Syndrome (MDS)

June 17th 2022

Dr Gustavo Rivero discusses how and where tamibarotene might fit into the treatment landscape for patients with higher-risk myelodysplastic syndrome (MDS).

Inside the Clinic: Basal Cell Carcinoma Treatment Advances

June 16th 2022

Jennifer Atlas, MD, and Shahab Babakoohi, MD, discuss advances in the treatment of patients with basal cell carcinoma and their treatment approaches to clinical scenarios based on updated data.

My Treatment Approach: Targeting HER2 in Metastatic Colorectal Cancer

June 15th 2022

An expert oncologist and pathologist discuss molecular testing in metastatic colorectal cancer and the current and upcoming options for HER2-targeted therapies.

Recent Updates on CDK4/6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

June 15th 2022

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

My Treatment Approach: The Evolving Treatment Landscape of Esophageal Squamous Cell Carcinoma

June 8th 2022

Expert provides an overview of esophageal squamous cell carcinoma (ESCC), discusses several key updates to the treatment landscape, and elucidates how clinicians can improve patient outcomes by applying data from the treatment algorithm.

My Treatment Approach: Acute Myeloid Leukemia (AML)

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, discuss recent advances in the treatment of newly-diagnosed acute myeloid leukemia and its impact on clinical practice.

My Treatment Approach: Bispecifics in Multiple Myeloma: Translating Evidence to Clinical Practice

May 26th 2022

Centering discussion on real-world patient scenarios, expert hematologist-oncologists review recent treatment advances in multiple myeloma with a focus on bispecifics and their impact on clinical practice.

Inside the Clinic: Myeloproliferative Neoplasms: Current and Future Standards of Care

April 28th 2022

Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms. 

My Treatment Approach: Metastatic Melanoma

April 26th 2022

Dr. Michael Atkins and Dr. Evan Lipson discuss the state of metastatic melanoma, contemporary and emerging treatment strategies, and break down a specific patient profile. Their conversation touches on the pros and cons of different treatment strategies for newly diagnosed patients as well as second- and third-line treatment strategies. Dr. Atkins and Dr. Lipson also take time to provide their personal experiences, preferences, and thoughts on prospects involving the treatment and management of metastatic melanoma.

My Treatment Approach: Applying Evidence to Clinical Practice to Improve Outcomes in Differentiated Thyroid Cancer

April 15th 2022

Experts in the field of differentiated thyroid cancer highlight recent advances in treatment by reviewing two real-world patient scenarios.

The Evolving Landscape of Molecular Alterations in NSCLC: Optimizing Testing and Treatment to Improve Outcomes

April 15th 2022

Expert oncologists share updates on the testing and treatment of molecular alterations in advanced non-small cell lung cancer.

The Evolving Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer

April 7th 2022

Shared insight on the evolving treatment armamentarium for metastatic CRPC and how expert physicians are optimizing care.

Improving Outcomes in Advanced RCC: Translating Evidence to Clinical Practice

April 5th 2022

A discussion on recent advances in the treatment of advanced renal cell carcinoma and their impact on clinical practice, illustrated by real-world patient profiles.

Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease

April 1st 2022

Expert perspectives on historical and novel treatment strategies for patients diagnosed with chronic graft-versus-host disease.

Inside the Clinic: Optimizing Outcomes in Patients With RCC: Translating Evidence to Clinical Practice

March 21st 2022

Centering discussion on patient profiles, expert panelists review recent advances in the treatment of renal cell carcinoma and their impact on clinical practice.